Cambria Gold Mines Inc. (TSXV: CAMB) (OTC Pink: AOTVF) ("Cambria" or the "Company") is pleased to announce new additions to the Management Team. These new members are in addition to recently announced ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated ...

Cambria Gold Mines Inc. (TSXV: CAMB) (OTC Pink: AOTVF) ("Cambria" or the "Company") is pleased to announce new additions to the Management ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial ...

A new way to escalate privileges inside Google’s Vertex AI highlights a broader problem: Enterprises have a level of trust in AI offerings that needs to be fundamentally reexamined. The finding of ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Men? Wearing pink? It’s more likely than you think. Earlier this month, a preppy Fair Isle holiday sweater by J.Crew, in an innocent shade of pink, caused uproar online after conservative commentator ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...